Christopher Tovey - GW Pharmaceuticals COO, Executive Director
Director
Mr. Christopher John Tovey is Chief Operating Officer, Executive Director of GW Pharmaceuticals PLC. Mr. Tovey has over 25 years experience in the pharmaceutical industry. Prior to joining our Company, Mr. Tovey was at UCB Pharmaceuticals from 2006 to 2012. Most recently, Mr. Tovey was the Vice President of Global Marketing Operations where he was responsible for worldwide marketing activities on a portfolio of UCB products generating over 2.0 billion in annual sales. Previous experience and roles at UCB included Managing Director Greece and Cyprus, and leader of all UCB activities on the orphan narcotic medication Xyrem, used in the treatment of narcolepsy. Mr. Tovey previously spent 18 years at GlaxoSmithKline plc in senior commercial roles in both the European and U.K. organizations. These roles included Director Commercial Strategy Distribution Europe, Director European Vaccine Therapy Director Commercial Development U.K., Director Vaccines Business Unit U.K. and Business Unit Manager Oncology U.K. While at GSK, Mr. Tovey worked across a wide range of therapeutic areas including infectious diseases, neurology, oncology, diabetes, respiratory, and immunology. since 2012.
Age | 48 |
Tenure | 12 years |
Phone | (44) 1223 235667 |
Web | www.gwpharm.com |
GW Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Samuel Scott | Bank Of New | 75 | |
John Hinshaw | Bank Of New | 48 | |
Loudon Owen | Academy Sports OutdoorsInc | N/A | |
Karin Ireton | Academy Sports OutdoorsInc | 59 | |
James Williams | Marine Products | 85 | |
Steven Black | Bank Of New | 65 | |
Jeffrey Goldstein | Bank Of New | 65 | |
Wesley Schack | Bank Of New | 70 | |
Pamela Rollins | Marine Products | 63 | |
Elizabeth Robinson | Bank Of New | 52 | |
Mark Nordenberg | Bank Of New | 68 | |
Larry Prince | Marine Products | 78 | |
Timothy Rollins | Marine Products | 58 | |
Chang Chan | Integrated Media Technology | 50 | |
William Richardson | Bank Of New | 73 | |
Edmund Kelly | Bank Of New | 74 | |
Linda Cook | Bank Of New | 62 | |
Jennifer Morgan | Bank Of New | 48 | |
Harry Cynkus | Marine Products | 70 | |
Linda Graham | Marine Products | 78 | |
john Luke | Bank Of New | 68 |
Management Performance
Return On Equity | -7.92 | |||
Return On Asset | -3.55 |
GW Pharmaceuticals Plc Leadership Team
Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Waldegrave, Non-Executive Independent Director | ||
Christopher Tovey, COO, Executive Director | ||
Thomas Lynch, Non-Executive Independent Director | ||
Catherine Mackey, Non-Executive Independent Director | ||
Justin Gover, CEO, Director | ||
Geoffrey Guy, Executive Chairman of the Board | ||
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director | ||
Julian Gangolli, Executive Director | ||
Alicia Secor, Non-Executive Independent Director | ||
Adam George, CFO, Company Secretary, Director | ||
Cabot Brown, Non-Executive Independent Director | ||
Stephen Wright, Research & Development Director, Executive Director | ||
Darren Cline, Chief Commercial Officer, U.S. |
GWPH Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -7.92 | |||
Return On Asset | -3.55 | |||
Profit Margin | (11.03) % | |||
Operating Margin | (9.82) % | |||
Current Valuation | 6.42 B | |||
Shares Outstanding | 31.54 M | |||
Shares Owned By Insiders | 0.20 % | |||
Shares Owned By Institutions | 80.35 % | |||
Number Of Shares Shorted | 693.73 K | |||
Price To Earning | 126.70 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Transaction History View history of all your transactions and understand their impact on performance | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |